Brought to you by 
Series B for neuro start-up CoLucid raises $25mm
03 Jul 2008
Executive Summary
First-time backer Care Capital has led the $25mm Series B financing for CoLucid Pharmaceuticals (lead candidate for migraine plus preclinical programs for several other neurological diseases) and contributed a new board member to the company. Returning shareholders Pappas Ventures, Domain Associates, Pearl Street Venture Funds, and Triathlon Medical Ventures also participated. CoLucid will use to money to move its 5HT1F agonist COL144 into Phase III and test the compound's anti-migraine efficacy as an oral medicine.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com